{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:17:08Z","timestamp":1762157828958,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":639,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/16\/1\/31699","PG\/15\/47\/31591","PG\/15\/79\/31777","PG\/17\/40\/33028"],"award-info":[{"award-number":["FS\/16\/1\/31699","PG\/15\/47\/31591","PG\/15\/79\/31777","PG\/17\/40\/33028"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["14\/04478\u20105"],"award-info":[{"award-number":["14\/04478\u20105"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1111\/jth.14826","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T17:59:51Z","timestamp":1586627991000},"page":"1705-1713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combination of cyclic nucleotide modulators with P2Y12 receptor antagonists as anti\u2010platelet therapy"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-677X","authenticated-orcid":false,"given":"Paul C.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3242-2163","authenticated-orcid":false,"given":"Plinio M.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2154-1386","authenticated-orcid":false,"given":"Melissa V.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3506-6304","authenticated-orcid":false,"given":"Martina H.","family":"Lundberg Slingsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3164-512X","authenticated-orcid":false,"given":"Marilena","family":"Crescente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih\u2010Chin","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3509-8549","authenticated-orcid":false,"given":"Nicholas S.","family":"Kirkby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian J.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3988-4408","authenticated-orcid":false,"given":"Timothy D.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14826_bb0010","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/jth.14826_bb0015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST\u2010segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14826_bb0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti\u2010platelet therapy: cyclo\u2010oxygenase inhibition and the use of aspirin with particular regard to dual anti\u2010platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jth.14826_bb0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14826_bb0030","doi-asserted-by":"crossref","first-page":"s33","DOI":"10.1161\/ATVBAHA.107.160689","article-title":"P2Y12 antagonism: promises and challenges","volume":"28","author":"Michelson","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/jth.14826_bb0035","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1538-7836.2009.03714.x","article-title":"Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy","volume":"8","author":"Armstrong","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14826_bb0040","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/jth.14826_bb0045","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14826_bb0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0163-7258(96)00103-9","article-title":"Platelet prostanoid receptors","volume":"72","author":"Armstrong","year":"1996","journal-title":"Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1111\/jth.14826_bb0055","first-page":"S272","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2017\/18: enzymes","volume":"174","author":"Alexander","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1111\/jth.14826_bb0060","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1073\/pnas.93.4.1480","article-title":"cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase","volume":"93","author":"Moro","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.14826_bb0065","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1476-5381.1987.tb11367.x","article-title":"The anti\u2010aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide","volume":"92","author":"Radomski","year":"1987","journal-title":"Br J Pharmacol"},{"key":"10.1111\/jth.14826_bb0070","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bjp.0707224","article-title":"Recent developments in nitric oxide donor drugs","volume":"151","author":"Miller","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1111\/jth.14826_bb0075","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/bph.12980","article-title":"Extending the translational potential of targeting NO\/cGMP\u2010regulated pathways in the CVS","volume":"172","author":"Papapetropoulos","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1111\/jth.14826_bb0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","article-title":"Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure","volume":"34","author":"Erdmann","year":"2013","journal-title":"Eur Heart J"},{"issue":"Suppl","key":"10.1111\/jth.14826_bb0085","first-page":"S1","article-title":"Efficacy and safety data","volume":"151","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1111\/jth.14826_bb0090","doi-asserted-by":"crossref","first-page":"15782","DOI":"10.1073\/pnas.1218880110","article-title":"Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide","volume":"110","author":"Kirkby","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.14826_bb0095","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bcp.12826","article-title":"P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation","volume":"81","author":"Chan","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jth.14826_bb0100","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1182\/blood-2015-01-621656","article-title":"Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM\u20101 as a mediator of platelet\u2010monocyte interaction","volume":"126","author":"Armstrong","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.14826_bb0105","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.14826_bb0110","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the Management of Patients with Non\u2010ST\u2010Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.14826_bb0115","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4244\/EIJY15M11_07","article-title":"Long\u2010term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus\u2010eluting stent implantation: rationale and design of the GLOBAL LEADERS trial","volume":"12","author":"Vranckx","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1111\/jth.14826_bb0120","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high\u2010risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14826_bb0125","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/hrt.2010.205724","article-title":"Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?","volume":"96","author":"Warner","year":"2010","journal-title":"Heart"},{"key":"10.1111\/jth.14826_bb0130","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14826_bb0135","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2011.04453.x","article-title":"Antiplatelet effects of aspirin vary with level of P2Y(1)(2) receptor blockade supplied by either ticagrelor or prasugrel","volume":"9","author":"Kirkby","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"343","key":"10.1111\/jth.14826_bb0140","first-page":"225","article-title":"The endothelium: maestro of the blood circulation","volume":"1994","author":"The","year":"1993","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1111\/jth.14826_bb0145","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/17474086.2016.1140035","article-title":"The importance of endothelium\u2010derived mediators to the efficacy of dual anti\u2010platelet therapy","volume":"9","author":"Warner","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1111\/jth.14826_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13028","article-title":"Platelet responses to pharmacological and physiological interventions in middle\u2010aged men with different habitual physical activity levels","volume":"223","author":"Lundberg Slingsby","year":"2018","journal-title":"Acta Physiol"},{"key":"10.1111\/jth.14826_bb0155","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO\u2010independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/jth.14826_bb0160","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-540-68964-5_13","article-title":"NO\u2010independent, haem\u2010dependent soluble guanylate cyclase stimulators","volume":"191","author":"Stasch","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1111\/jth.14826_bb0165","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.cellsig.2016.06.012","article-title":"Soluble guanylyl cyclase\u2010activated cyclic GMP\u2010dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP\u2010serine 239 phosphorylation","volume":"28","author":"Holt","year":"2016","journal-title":"Cell Signal"},{"key":"10.1111\/jth.14826_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047223","article-title":"Activation of haem\u2010oxidized soluble guanylyl cyclase with BAY 60\u20132770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway","volume":"7","author":"Mendes\u2010Silverio","year":"2012","journal-title":"PLoS One"},{"key":"10.1111\/jth.14826_bb0175","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14826_bb0180","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.107.124248","article-title":"2\u2010[4\u2010[(5,6\u2010diphenylpyrazin\u20102\u2010yl)(isopropyl)amino]butoxy]\u2010N\u2010(methylsulfonyl)acetam ide (NS\u2010304), an orally available and long\u2010acting prostacyclin receptor agonist prodrug","volume":"322","author":"Kuwano","year":"2007","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14826","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14826","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14826","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622013332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622013332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:28:52Z","timestamp":1761535732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622013332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1538783622013332"],"URL":"https:\/\/doi.org\/10.1111\/jth.14826","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of cyclic nucleotide modulators with P2Y12 receptor antagonists as anti\u2010platelet therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}